Non-Hodgkin Lymphoma Shows Significantly Better Outcomes with Obinutuzumab, Bendamustine Combo
News
Patients with non-Hodgkin lymphoma (NHL) who are resistant to rituximab therapies show greater benefits when treated with a obinutuzumab and bendamustine combination, compared to the standard bendamustine alone, according to data from the ... Read more